1 minute read
Jan. 17, 2022
Ulotaront: a TAAR1 GPCR Agonist with 5-HT1A Receptor Activity for Schizophrenia
ulotaront
TAAR1 GPCR agonist phase III candidate for schizophrenia from in vivo phenotypic screening ACS Medicinal Chemistry Letters Sunovion Pharmaceuticals, Marlborough, MA
Reviewer:
Loading...
